ArticleWorld journal of surgical oncology2016
Complete remission of pancreatic head desmoid tumor treated by COX-2 inhibitor-a case report.
Article in World journal of surgical oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 28 citations in OpenAlex.
- Radiological features of pancreatic desmoid-type fibromatosis: a case series and systematic review.Abdominal radiology (New York) · 2025Pooled it
- Efficacy and safety of cyclooxygenase 2 inhibitors for desmoid tumor management: a systematic review.Nagoya journal of medical science · 2021Pooled it
- Aggressive atypical cystic fibromatosis of the pancreas: a case report and literature review.Frontiers in oncology · 2025Article
- Challenging Diagnostic Dilemma: Mesenteric Desmoid Tumor Masquerading as Perforated Peritonitis.Cureus · 2023Article
- Large Desmoid Tumor of the Pancreas: A Report of a Rare Case and Review of the Literature.The American journal of case reports · 2022Review
- Mesenchymal Tumors Involving the Pancreas: A Clinicopathologic Analysis and Review of the Literature.Turk patoloji dergisi · 2022Review
- Desmoid type fibromatosis of the distal pancreas: A case report.Annals of hepato-biliary-pancreatic surgery · 2021Article
- Paediatric desmoid tumour of the head and neck: a complete response to chemotherapy and the paradigm shift towards non-surgical management.BMJ case reports · 2021Article
- Management of aggressive fibromatosis.Oncology letters · 2021Review
- Desmoid Tumors Characteristics, Clinical Management, Active Surveillance, and Description of Our FAP Case Series.Journal of clinical medicine · 2020Review
- Desmoid fibromatosis of the pancreas--A case report with radiologic-pathologic correlation.Radiology case reports · 2020Article
- Combination therapy with sorafenib and celecoxib for pediatric patients with desmoid tumor.Pediatric hematology and oncology · 2020Article
- Enhanced T-lymphocyte infiltration in a desmoid tumor of the thoracic wall in a young woman treated with intratumoral injections of the oncolytic peptide LTX-315: a case report.Journal of medical case reports · 2019Article
- An unusual finding in a desmoid-type fibromatosis of the pancreas: a case report and review of the literature.Journal of medical case reports · 2018Review
- Effective treatment of aggressive fibromatosis with celecoxib guided by genetic testing.Cancer biology & therapy · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDesmoid tumors (DTs) are non-metastatic, locally aggressive neoplasms with high postoperative recurrence rates. The pancreas is an extremely rare location for DTs. The local control of DTs is challenging. Surgery and radiotherapy are currently the principal treatment modalities for DTs; however, some resections might not be radical, and radiotherapy has several drawbacks. Therefore, many studies have been focusing on the molecular pathways involved in DTs in order to develop molecular-targeted therapies or chemotherapy. Cyclooxygenase-2 (COX-2) has been demonstrated to play a role in the growth of DTs, and the pharmacologic blockade of COX resulted in decreased cell proliferation in desmoid cell cultures in vitro. CASE PRESENTATION: Herein, we report a 57-year-old woman who presented with recurrent epigastric pain and weight loss. An abdominal computed tomography scan showed an approximately 10-cm mass over the pancreatic head region and dilatation of the pancreatic duct. Tumor biopsy and bypass surgery were performed. A DT was confirmed on pathologic analysis. After resection, we prescribed treatment with the COX-2 inhibitor celecoxib. The patient showed complete remission and there was no local recurrence or distant metastasis within the 24-month follow-up period.
conclusionsThe outcome of this case study is encouraging, and long-term follow-up studies are required to establish the effect of treatment with celecoxib on the prognosis of DTs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.